Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) traded down 3.8% during trading on Friday . The stock traded as low as $1.90 and last traded at $1.8850. Approximately 309,988 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 1,803,238 shares. The stock had previously closed at $1.96.
Analyst Upgrades and Downgrades
AUTL has been the subject of a number of research reports. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, August 3rd. Finally, Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.
Get Our Latest Stock Analysis on AUTL
Autolus Therapeutics Stock Down 3.8%
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. The business had revenue of $45.69 million during the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. Analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.75 EPS for the current year.
Hedge Funds Weigh In On Autolus Therapeutics
A number of institutional investors have recently bought and sold shares of AUTL. GAMMA Investing LLC lifted its stake in Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after buying an additional 8,309 shares in the last quarter. Independent Advisor Alliance purchased a new position in shares of Autolus Therapeutics in the fourth quarter worth approximately $28,000. Marex Group plc purchased a new position in shares of Autolus Therapeutics in the second quarter worth approximately $28,000. Waverly Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the first quarter valued at approximately $37,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of Autolus Therapeutics during the fourth quarter valued at approximately $43,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.
Autolus Therapeutics Company Profile
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.
The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.
Read More
- Five stocks we like better than Autolus Therapeutics
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
- Oracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in Earnings
- TSMC Revenue Jumps 53% in August, Signaling Strong AI Chip Demand
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
